Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Liraglutide, a long-lasting glucagon‑like peptide‑1 analogue, has been used for the treatment of patients with type 2 diabetes mellitus since 2009. In this study, we investigated the anti-diabetic effects and mechanisms of action of liraglutide in a spontaneous diabetic animal model, using KK/Upj-Ay/J (KKAy) mice. The KKAy mice were divided into 2 groups, the liraglutide group (mice were treated with 250 µg/kg/day liraglutide) and the model group (treated with an equivalent amount of normal saline). C57BL/6J mice were used as the controls (treated with an equivalent amount of normal saline). The treatment period lasted 6 weeks. During this treatment period, fasting blood glucose (FBG) levels and the body weight of the mice were measured on a weekly basis. Our results revealed that liraglutide significantly decreased FBG levels, the area under the curve following a oral glucose tolerance test and insulin tolerance test, increased serum insulin levels, reduced homeostasis model assessment of insulin resistance and increased the insulin sensitivity index. Furthermore, liraglutide ameliorated glycometabolism dysfunction by increasing glycolysis via hexokinase and glycogenesis via pyruvate kinase activation. An ultrastructural examination of the pancreas revealed that liraglutide improved the damaged state of islet β cells and increased the number of insulin secretory granules. The real-time PCR results revealed that the gene expression of glucose transporter 4 (GLUT4) increased following treatment with liraglutide. Liraglutide also upregulated the protein expression of GLUT4 in liver tissue and skeletal muscle. Our results suggest that liraglutide ameliorates glycometabolism and insulin resistance in diabetic KKAy mice by stimulating insulin secretion, increasing glycogenesis and glycolysis and upregulating the expression of GLUT4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dual Role of Interleukin-6 in Regulating Insulin Sensitivity in Murine Skeletal Muscle
Nieto-Vazquez, I., Fernández-Veledo, S., de Alvaro, C., & Lorenzo, M. (2008) · Diabetes · doi:10.2337/db07-1062 · Cited by 209 · cited 1×
“Studies had been found that insulin resistance is related to a decrease in GLUT4 expression (46).”
RetractedCritical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760 · cited 1×
“The InsR substrate family, such as IRS-1 and IRS-2, is phosphorylated and combines with the regulatory subunit of PI3K and passes insulin signaling to the protein kinase B (Akt) molecule, leading to the induction of a variety of insulin bioactivities, thus improving insulin resistance (11,40-43).”
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Sun, Q., Chen, X., Ma, J., Peng, H., Wang, F., Zha, X., Wang, Y., Jing, Y., Yang, H., Chen, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014769108 · Cited by 586
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 1×
“Liraglutide, marketed under the brand name, Victoza, is a long-acting GLP-1 agonist developed by Novo Nordisk (Bagsvaerd, Denmark) for the treatment of type 2 diabetes (8).”
Tersey, S. A., Nishiki, Y., Templin, A. T., Cabrera, S. M., Stull, N. D., Colvin, S. C., Evans-Molina, C., Rickus, J. L., Maier, B., & Mirmira, R. G. (2012) · Diabetes · doi:10.2337/db11-1293 · Cited by 353 · cited 1×
“Islet β cell dysfunction induces insulin secretion disorders and hyperglycemia (33,34).”
Subcellular localization of hexokinases I and II directs the metabolic fate of glucose
John, S., Weiss, J. N., & Ribalet, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017674 · Cited by 239 · cited 1×
“Activated HK promotes glycogen synthesis and glycolysis (24,25).”
Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes
Rosengren, A. H., Braun, M., Mahdi, T., Andersson, S. A., Travers, M. E., Shigeto, M., Zhang, E., Almgren, P., Ladenvall, C., Axelsson, A. S., et al. (2012) · Diabetes · doi:10.2337/db11-1516 · Cited by 237 · cited 1×
“Islet β cell dysfunction induces insulin secretion disorders and hyperglycemia (33,34).”
Gault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125 · cited 2×
“Our present results demonstrate that treatment with liraglutide reduces FBG levels, lowers the AUC following OGTT and ITT, lowers the HOMA-IR index, increases insulin levels, ameliorates glucose tolerance and insulin sensitivity in diabetic KKAy mice, which are consistent with the results from the abovementioned studi…”
GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104 · cited 1×
“secreted by intestinal L-cells, has several physiological functions, such as lowering blood glucose levels and increasing insulin secretion (5-7).”
Giannocco, G., Oliveira, K. C., Crajoinas, R. O., Venturini, G., Salles, T. A., Fonseca-Alaniz, M. H., Maciel, R. M. B., & Girardi, A. C. C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.043 · Cited by 68
Cited by
Chow, H.-M., Shi, M., Cheng, A., Gao, Y., Chen, G., Song, X., So, R. W. L., Zhang, J., & Herrup, K. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0505-1 · Cited by 171
Identification of anti-diabetes peptides from Spirulina platensis
Hu, S., Fan, X., Qi, P., & Zhang, X. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.03.024 · Cited by 150
Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets
HUANG, C., YUAN, L., & CAO, S. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2207 · Cited by 41
Ji, W., Chen, X., Lv, J., Wang, M., Ren, S., Yuan, B., Wang, B., & Chen, L. (2014) · International Journal of Endocrinology · doi:10.1155/2014/312452 · Cited by 36
Self-citation
Metadata
- Authors
- CHEN, L.-N., LYU, J., YANG, X.-F., JI, W.-J., YUAN, B.-X., CHEN, M.-X., MA, X., & WANG, B.
- Venue
- International Journal of Molecular Medicine
- Publisher
- Spandidos Publications
- Published
- 2013-07-19
- Volume
- 32
- Issue
- 4
- Pages
- 892-900
- ISSN
- 1107-3756 (ISSN-L)
- 1791-244X
- OpenAlex
- W1982723155
- Cited by
- 50
- References
- 11
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.